IHCH-3064
Product Specifications
UNSPSC Description
IHCH-3064 is a dual-acting compounds targeting Adenosine A2A Receptor and HDAC. IHCH-3064 exhibits potent binding to A2AR (Ki=2.2 nM) and selective inhibition of HDAC1 (IC50=80.2 nM), with good antiproliferative activity against tumor cell lines in vitro. IHCH-3064 is a tumor immunotherapeutic agent.
Target Antigen
Adenosine Receptor; HDAC
Type
Reference compound
Related Pathways
Cell Cycle/DNA Damage;Epigenetics;GPCR/G Protein
Applications
COVID-19-anti-virus
Field of Research
Cancer; Inflammation/Immunology
Assay Protocol
https://www.medchemexpress.com/ihch-3064.html
Solubility
10 mM in DMSO
Smiles
O=C(C1=CC=C(CCN2N=CC3=C2N=C(N)N4N=C(C5=CC=CO5)N=C34)C=C1)NC6=C(N)C=CC=C6
Molecular Weight
479.49
References & Citations
[1]Wenzhong Yan, et al. Structure-Based Design of Dual-Acting Compounds Targeting Adenosine A 2A Receptor and Histone Deacetylase as Novel Tumor Immunotherapeutic Agents. J Med Chem. 2021 Nov 25;64(22):16573-16597.
Shipping Conditions
Room temperature
Product Datasheet
http://file.medchemexpress.com/batch_PDF/HY-145406/IHCH-3064-DataSheet-MedChemExpress.pdf
Product MSDS
http://file.medchemexpress.com/batch_PDF/HY-145406/
Clinical Information
No Development Reported
CAS Number
2420562-65-6
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
